CClinicalTrials.gg
Not yet recruitingNCT07767825Updated Aug 17, 2026

Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Fetuses With Severe CDH

An interventional study of Goldballoon Detachable Balloon (GOLDBAL2) in Severe Congenital Diaphragmatic Hernia, sponsored by NYU Langone Health. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this pilot study is to evaluate the feasibility of using Fetoscopic Endoluminal Tracheal Occlusion (FETO) in 10 pregnant individuals carrying fetuses with severe congenital diaphragmatic hernia (CDH). FETO surgery will be performed at 27 weeks - 29 weeks and 6 days of gestation, and the fetoscopic removal of the balloon will be performed at 34 weeks - 34 weeks and 6 days of gestation. The primary endpoint is successful placement and removal of the balloon.

02

Conditions studied

  • Severe Congenital Diaphragmatic Hernia
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Provision of a signed and dated informed consent form
  2. Pregnant individuals age 18 years and older
  3. Singleton pregnancy
  4. A normal karyotype with confirmation by culture results, CMA with non-pathologic variants, whole exome or genome sequencing (WES or WGS).
  5. Isolated left CDH with severe pulmonary hypoplasia with o/e LHR less than 25% with liver up (measured at 18 weeks 0 days to 29 weeks 5 days of gestation)
  6. Isolated right CDH with severe pulmonary hypoplasia with o/e LHR equal or less than 30% with liver up (measured at 18 weeks 0 days to 29 weeks 5 days of gestation)
  7. Gestational age at FETO procedure 27 weeks 0 days to 29 weeks 6 days as determined by clinical information (LMP) and evaluation of first ultrasound
  8. Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
  9. Willing to reside within a 30-minute distance of the NYULH in the time period between the FETO placement procedure and the balloon retrieval procedure, and ability to maintain follow-up appointments
  10. The subject has a support person (e.g., spouse, partner, friend, parent) who is available to stay with her for the duration of the pregnancy near NYULH.
  11. Willing to comply with restrictions of daily living, including inability to exercise, have intercourse, or return to work
  12. Meets psychosocial criteria

Exclusion criteria

Exclusion Criteria:

  1. Natural rubber latex allergy
  2. Additional fetal anomaly and chromosomal abnormalities, associated anomalies recognized to alter survival prognosis (i.e., congenital heart disease) or presence of an underlying genetic syndrome (i.e., Fryns) by ultrasound, MRI or echocardiogram at the fetal treatment center.
  3. Signs of preterm labor, cervix shortened to ≤20 mm at enrollment or at 24 hours prior to FETO balloon insertion procedure) or a uterine anomaly strongly predisposing to preterm labor.
  4. Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy
  5. History of incompetent cervix with or without cerclage
  6. Placental abnormalities (previa, abruption, accreta, chorioangioma) known at time of enrollment
  7. Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy
  8. Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment
  9. Uterine anomaly such as large or multiple fibroids or mullerian duct abnormality
  10. There is no safe or technically feasible fetoscopic approach to balloon placement
  11. Participation in another intervention study that influences maternal and fetal morbidity and mortality
  12. Any other condition which, in the opinion of the investigator, would compromise safety, feasibility or impede compliance.
  13. Bilateral CDH, isolated left sided CDH with o/e LHR >/= 25% and isolated right sided CDH >30%
  14. No intrathoracic liver herniation
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Congenital diaphragmatic hernia (CDH)

    FETO surgery will be performed at 27 weeks - 29 weeks and 6 days of gestation, and the fetoscopic removal of the balloon will be performed at 34 weeks - 34weeks and 6 days of gestation.

    Device: Goldballoon Detachable Balloon (GOLDBAL2)

Interventions

  • DeviceGoldballoon Detachable Balloon (GOLDBAL2)

    GOLDBAL2 will be inserted into the fetal trachea and deployed with the Delivery Microcatheter (BALTACCI-BDPE100).

05

What researchers measure

Primary outcomes

  1. Number of successful balloon placements at age 27w0d - 29w6d and removal at 34 weeks of gestation

    Time frame: Up to 35 weeks

Secondary outcomes

  1. Difference between the relative lung volume (o/e LHR and o/e TLV)

    Fetal lung growth will be calculated by the difference between the relative lung volume (observed-to-expected (o/e) lung-to-head ratio (LHR) and o/e total lung volume (TLV)) measured before and after FETO

    Time frame: Baseline, removal of balloon (up to 35 weeks)

06

Study locations

1 site
  • NYU Langone Health
    New York, New York 10016, United States
07

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: jose.peiro@nyulangone.org. Besides the study publications, by FDA regulation, the data will be shared with the NAFTNet FETO registry, which will involve all of the individual participant data collected during the trial, after deidentification. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Sap

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07767825
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Aug 17, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
Sep 2031 (estimated)
Last update
Aug 17, 2026

Study contacts

Erin Lonergan, MHA, BSN, RN
Contact
Erin.lonergan@nyulangone.org
212-814-4261
Jose L. Peiro, MD, PhD
Contact
Jose.peiro@nyulangone.org
212-263-7391
Jose L. Peiro, MD, PhD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion